2022
1188TiP ORCHARD platform study: Osimertinib + datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib
De Langen J, Cho B, Piotrowska Z, Le X, Goldberg S, Goldman J, Okamoto I, Hewson N, Maidment J, Tang K, Veney N, Cosaert J, Lau J, Dressman M, Ambrose H, Riess J, Yu H. 1188TiP ORCHARD platform study: Osimertinib + datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib. Annals Of Oncology 2022, 33: s1091-s1092. DOI: 10.1016/j.annonc.2022.07.1311.Peer-Reviewed Original Research
2021
1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib
Yu H, Ambrose H, Baik C, Cho B, Cocco E, Goldberg S, Goldman J, Kraljevic S, de Langen A, Okamoto I, Piotrowska Z, Pluta M, Powar S, Aransay N, Riess J, Le X. 1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib. Annals Of Oncology 2021, 32: s978-s979. DOI: 10.1016/j.annonc.2021.08.1844.Peer-Reviewed Original ResearchP76.27 ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line Osimertinib
Cho B, Piotrowska Z, Le X, Goldberg S, Goldman J, De Langen A, Okamoto I, Smith P, Mensi I, Maidment J, Hartmaier R, Li M, Doughton G, Patel G, Pease J, Szekeres P, Riess J, Yu H. P76.27 ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line Osimertinib. Journal Of Thoracic Oncology 2021, 16: s598. DOI: 10.1016/j.jtho.2021.01.1084.Peer-Reviewed Original ResearchFirst-line osimertinib
2020
Drug Sensitivity and Allele‐specificity of First‐line Osimertinib Resistance EGFR Mutations
Starrett J, Guernet A, Cuomo M, Poels K, van Rosenburgh I, Nagelberg A, Farnsworth D, Price K, Khan H, Ashtekar K, Gaefele M, Ayeni D, Stewart T, Kuhlmann A, Kaech S, Unni A, Homer R, Lockwood W, Michor F, Goldberg S, Lemmon M, Smith P, Cross D, Politi K. Drug Sensitivity and Allele‐specificity of First‐line Osimertinib Resistance EGFR Mutations. The FASEB Journal 2020, 34: 1-1. DOI: 10.1096/fasebj.2020.34.s1.00612.Peer-Reviewed Original ResearchFirst-line osimertinibEGFR-mutant lung cancerMutant lung cancerOsimertinib treatmentEGFR-TKILung cancerEGFR mutationsTotal tumorsPreferred first-line therapySecondary mutationsThird-generation EGFR-TKIFirst-line osimertinib treatmentMichael Smith FoundationResistance EGFR mutationsFirst-line therapySecondary EGFR mutationGeneration EGFR-TKISubsequent treatment approachesTransgenic mouse modelLung cancer researchTumor volume changesCoronal MR imagesTumor volume measurementsNew Investigator AwardResistance mechanisms